Use-dependent modulation of myocardial conduction by a new class of HERG agonists: deal breaker or cherry on top?
Akar
Fadi G
FG
D000200:Action Potentials; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D051638:Ether-A-Go-Go Potassium Channels / Q000819:agonists* / Q000378:metabolism; D006168:Guinea Pigs; D006329:Heart Conduction System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D010671:Phenylurea Compounds / Q000009:adverse effects / Q000494:pharmacology*; D011188:Potassium / Q000378:metabolism*; D018570:Risk Assessment; D013777:Tetrazoles / Q000009:adverse effects / Q000494:pharmacology*; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D051638:Ether-A-Go-Go Potassium Channels; C423868:NS 3623; D010671:Phenylurea Compounds; D013777:Tetrazoles; D011188:Potassium